ArticleFrontiers in public health2026
Quality and reliability of semaglutide content on different Chinese short video platforms: a study focusing on side effects.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to evaluate the quality, reliability, and content characteristics of semaglutide-related short videos on three major Chinese short-video platforms (Bilibili, TikTok, and Rednote), with a focus on exploring differences in the presentation of side effects across different platforms and uploader types. Rather than examining specific clinical indications or dosing regimens, this study focuses on how semaglutide-related information is presented to the general public in real-world short-video contexts. It seeks to clarify the impact of platform ecology and creator identity on drug information dissemination, thereby providing a basis for optimizing the quality of online health information and conducting targeted public health communication. Methods: A cross-sectional content analysis was adopted. Semaglutide-related videos were retrieved from three major Chinese short-video platforms using the Chinese keyword "" (the standard Mandarin term for "semaglutide"). This exact search term was used to simulate real-world user behavior and ensure reproducibility across platforms. Because most videos did not specify approved indications (type 2 diabetes vs. obesity) or dosage levels, analyses were conducted without stratification by clinical dose or indication. After rigorous screening, eligible videos were assessed for quality and reliability using the modified DISCERN scale and Global Quality Score (GQS). Video content was categorized into five thematic dimensions, and mentions of nine predefined side effects were systematically recorded. A dual-perspective analytical approach-comparing the full sample and a side effect-focused subsample-was employed to examine platform-based differences in adverse event portrayal. Results: A total of 607 semaglutide-related videos were included (Bilibili: 309, TikTok: 153, Rednote: 145). The results showed significant differences in content quality (M-DISCERN and GQS scores), video duration, and user engagement metrics across platforms ( Conclusion: The quality and reliability of semaglutide-related short videos are significantly influenced by platform ecology. Publicly accessible drug information on short-video platforms often lacks clear differentiation between approved indications and dosage regimens, contributing to generalized interpretations of drug risks. The drug information accessible to the public exhibits structural biases, with side effect narratives demonstrating a clear "platformization" pattern. The dual-perspective analysis revealed that inter-platform differences in the portrayal of specific adverse events (e.g., gastrointestinal and hepatobiliary effects) were more discernible in the side effect-focused subsample. Future interventions should be tailored to platform-specific features to enhance the completeness and scientific rigor of online pharmaceutical information.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.